Published in Biol Psychiatry on February 04, 2010
Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals. Neuropsychopharmacology (2011) 1.18
Delayed procedural learning in α7-nicotinic acetylcholine receptor knockout mice. Genes Brain Behav (2011) 1.08
Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol (2014) 1.04
Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil. Neuropsychopharmacology (2011) 0.94
Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia. Eur Neuropsychopharmacol (2013) 0.92
Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice. Int J Neuropsychopharmacol (2012) 0.91
Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania. Psychopharmacology (Berl) (2012) 0.90
Modafinil attenuates reinstatement of cocaine seeking: role for cystine-glutamate exchange and metabotropic glutamate receptors. Addict Biol (2012) 0.89
Consideration of species differences in developing novel molecules as cognition enhancers. Neurosci Biobehav Rev (2012) 0.87
Ascending caudal medullary catecholamine pathways drive sickness-induced deficits in exploratory behavior: brain substrates for fatigue? Brain Behav Immun (2010) 0.85
Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. Front Neurosci (2013) 0.83
Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants. Prog Neurobiol (2012) 0.83
Examining the genetic and neural components of cognitive flexibility using mice. Physiol Behav (2012) 0.80
GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders. Neuropsychopharmacology (2015) 0.80
Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics (2011) 0.80
Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol (2015) 0.79
Humor as a reward mechanism: event-related potentials in the healthy and diseased brain. PLoS One (2014) 0.79
Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features. Psychopharmacology (Berl) (2015) 0.77
Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies. Neurosci Biobehav Rev (2015) 0.77
Investigating the mechanism(s) underlying switching between states in bipolar disorder. Eur J Pharmacol (2015) 0.77
Effect of armodafinil on cognition in patients with HIV/AIDS and fatigue. J Clin Exp Neuropsychol (2013) 0.76
The effects of reduced dopamine transporter function and chronic lithium on motivation, probabilistic learning, and neurochemistry in mice: Modeling bipolar mania. Neuropharmacology (2016) 0.76
Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania. Psychopharmacology (Berl) (2017) 0.75
The role of neuroplasticity and cognitive reserve in aging with HIV: recommendations for cognitive protection and rehabilitation. J Neurosci Nurs (2013) 0.75
Modafinil Induces Rapid-Onset Behavioral Sensitization and Cross-Sensitization with Cocaine in Mice: Implications for the Addictive Potential of Modafinil. Front Pharmacol (2016) 0.75
Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA (2009) 3.04
Dopaminergic role in stimulant-induced wakefulness. J Neurosci (2001) 2.91
Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology (2007) 2.88
Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol (2006) 2.60
Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther (2006) 2.04
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther (2009) 1.88
Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. J Neurosci (2007) 1.73
Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci (2008) 1.72
Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep (1994) 1.62
Reinforcing effects of modafinil: influence of dose and behavioral demands following drug administration. Psychopharmacology (Berl) (2005) 1.39
Spatial learning deficit in dopamine D(1) receptor knockout mice. Eur J Pharmacol (1999) 1.27
Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology (2004) 1.23
GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology (Berl) (2009) 1.14
Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience (2005) 1.11
Differential contributions of dopaminergic D1- and D2-like receptors to cognitive function in rhesus monkeys. Psychopharmacology (Berl) (2006) 1.01
Dopamine in the orbitofrontal cortex regulates operant responding under a progressive ratio of reinforcement in rats. Neurosci Lett (2004) 0.97
Attenuation of sucrose reinforcement in dopamine D1 receptor deficient mice. Eur J Neurosci (2003) 0.97
Modafinil-induced psychosis. Intern Med J (2008) 0.92
Apathy is associated with executive functioning in first episode psychosis. BMC Psychiatry (2009) 0.89
Free operant and discrete trial performance of mice in the nine-hole box apparatus: validation using amphetamine and scopolamine. Psychopharmacology (Berl) (2004) 0.83
Habituation revisited: an updated and revised description of the behavioral characteristics of habituation. Neurobiol Learn Mem (2008) 3.23
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov (2012) 2.44
Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology (2008) 2.16
A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry (2006) 1.93
A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry (2009) 1.69
Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther (2009) 1.67
Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry (2003) 1.48
Studies in genetically modified mice suggest novel mechanisms of mood regulation. Biol Psychiatry (2010) 1.38
Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology (2006) 1.33
Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS. Schizophr Bull (2008) 1.32
A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev (2007) 1.29
Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One (2012) 1.28
Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry (2003) 1.28
Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci (2004) 1.26
Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci (2002) 1.24
5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology (2009) 1.24
Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res (2009) 1.20
The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One (2009) 1.20
The quantitative assessment of motor activity in mania and schizophrenia. J Affect Disord (2010) 1.18
Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder. Neuropsychopharmacology (2012) 1.17
Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. Psychiatry Res (2003) 1.17
Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models. Neurosci Biobehav Rev (2013) 1.16
A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics. Int J Neuropsychopharmacol (2006) 1.15
The relationship of age to prepulse inhibition and habituation of the acoustic startle response. Biol Psychol (2003) 1.15
GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology (Berl) (2009) 1.14
Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology (2007) 1.13
Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol (2013) 1.13
The mouse attentional-set-shifting task: a method for assaying successful cognitive aging? Cogn Affect Behav Neurosci (2010) 1.11
Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) (2003) 1.11
Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Res (2004) 1.10
Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS One (2009) 1.10
Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice. Biol Psychiatry (2008) 1.07
Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophr Res (2002) 1.06
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology (2011) 1.06
Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology (2003) 1.05
Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis--a longitudinal study. Eur Arch Psychiatry Clin Neurosci (2004) 1.05
Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol (2011) 1.04
Animal models of schizophrenia. Curr Top Behav Neurosci (2010) 1.04
Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull (2005) 1.04
Heart rate variability in bipolar mania and schizophrenia. J Psychiatr Res (2009) 1.03
Prepulse inhibition and P50 suppression: commonalities and dissociations. Psychiatry Res (2006) 1.03
The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacol Biochem Behav (2010) 1.02
Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Res (2010) 1.02
Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) (2003) 1.02
Repeated assessment of exploration and novelty seeking in the human behavioral pattern monitor in bipolar disorder patients and healthy individuals. PLoS One (2011) 1.02
CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology (2008) 1.02
Sept5 deficiency exerts pleiotropic influence on affective behaviors and cognitive functions in mice. Hum Mol Genet (2009) 1.01
Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology (2007) 1.01
Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. J Psychopharmacol (2011) 1.00
GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology (2002) 1.00
Information-processing deficits and cognitive dysfunction in panic disorder. J Psychiatry Neurosci (2005) 0.99
The challenge of connecting the dots in the B.R.A.I.N. Neuron (2013) 0.99
Predictors of risk and resilience for posttraumatic stress disorder among ground combat Marines: methods of the Marine Resiliency Study. Prev Chronic Dis (2012) 0.98
Perceptual measurement in schizophrenia: promising electrophysiology and neuroimaging paradigms from CNTRICS. Schizophr Bull (2011) 0.98
Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders. Curr Top Behav Neurosci (2012) 0.97
The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behav Brain Res (2011) 0.97
Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders. Hum Mol Genet (2010) 0.97
Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol (2010) 0.97
Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci Biobehav Rev (2010) 0.97
Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav Brain Res (2012) 0.97
The balance between approach and avoidance behaviors in a novel object exploration paradigm in mice. Behav Brain Res (2004) 0.97
Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav Pharmacol (2008) 0.97
Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biol Psychiatry (2002) 0.96
Contributions of dopamine D1, D2, and D3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice. Neuropsychopharmacology (2007) 0.96
The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl) (2006) 0.96
Cortical grey matter volume and sensorimotor gating in schizophrenia. Cortex (2008) 0.95
Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology (2006) 0.95
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther (2006) 0.95
Neurobiological measures of schizotypal personality disorder: defining an inhibitory endophenotype? Am J Psychiatry (2002) 0.95
The acoustic startle reflex and its modulation: effects of age and gender in humans. Biol Psychol (2003) 0.95
Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology (2011) 0.95
The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology (2004) 0.95
Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology (Berl) (2008) 0.95
Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology (2003) 0.95
Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil. Neuropsychopharmacology (2011) 0.94
Prepulse inhibition and "psychosis-proneness" in healthy individuals: an fMRI study. Eur Psychiatry (2008) 0.92
Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacology (Berl) (2002) 0.92
Anxiogenic treatments do not increase fear-potentiated startle in mice. Biol Psychiatry (2005) 0.92
The effects of sex and neonatal maternal separation on fear-potentiated and light-enhanced startle. Behav Brain Res (2005) 0.92
Four factors underlying mouse behavior in an open field. Behav Brain Res (2012) 0.91
Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology (2006) 0.91
Yohimbine disrupts prepulse inhibition in rats via action at 5-HT1A receptors, not alpha2-adrenoceptors. Psychopharmacology (Berl) (2005) 0.91
Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice. Int J Neuropsychopharmacol (2012) 0.91
Isolation rearing of mice induces deficits in prepulse inhibition of the startle response. Behav Brain Res (2006) 0.91
RO-10-5824 is a selective dopamine D4 receptor agonist that increases novel object exploration in C57 mice. Neuropharmacology (2003) 0.90
Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania. Psychopharmacology (Berl) (2012) 0.90
Prolonged Ketamine Effects in Sp4 Hypomorphic Mice: Mimicking Phenotypes of Schizophrenia. PLoS One (2013) 0.90
Inhibitory deficits in euthymic bipolar disorder patients assessed in the human behavioral pattern monitor. J Affect Disord (2013) 0.89
Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs. Neuropsychopharmacology (2003) 0.89
Age-associated improvements in cross-modal prepulse inhibition in mice. Behav Neurosci (2010) 0.89
Attentional modulation of prepulse inhibition: a new startle paradigm. Neuropsychobiology (2004) 0.88
Isolation rearing-induced deficits in contextual fear learning do not require CRF(2) receptors. Behav Brain Res (2010) 0.88
An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition. J Pharmacol Exp Ther (2005) 0.88
Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. Biol Psychiatry (2007) 0.88
Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacology (Berl) (2013) 0.88
MDMA "ecstasy" alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. Psychopharmacology (Berl) (2004) 0.88
Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology (2011) 0.87
5-HT₁A receptor binding is increased after recovery from bulimia nervosa compared to control women and is associated with behavioral inhibition in both groups. Int J Eat Disord (2010) 0.87
Patients with premenstrual dysphoric disorder have increased startle response across both cycle phases and lower levels of prepulse inhibition during the late luteal phase of the menstrual cycle. Neuropsychopharmacology (2007) 0.87
Habituation and sensitization of acoustic startle: opposite influences of dopamine D1 and D2-family receptors. Neurobiol Learn Mem (2008) 0.86